NPS Pharmaceuticals Given Average Recommendation of “Buy” by Brokerages (NASDAQ:NPSP)
NPS Pharmaceuticals (NASDAQ:NPSP) has earned an average recommendation of “Buy” from the fifteen analysts that are currently covering the company, Analyst Ratings Network.com reports. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $39.23.
NPS Pharmaceuticals (NASDAQ:NPSP) opened at 30.21 on Thursday. NPS Pharmaceuticals has a 52 week low of $21.60 and a 52 week high of $39.68. The stock has a 50-day moving average of $28.62 and a 200-day moving average of $30.22. The company has a market cap of $3.219 billion and a P/E ratio of 1514.50.
NPS Pharmaceuticals (NASDAQ:NPSP) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $56.10 million for the quarter, compared to the consensus estimate of $53.06 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. The company’s revenue for the quarter was up 53.7% on a year-over-year basis. On average, analysts predict that NPS Pharmaceuticals will post $0.03 earnings per share for the current fiscal year.
NPSP has been the subject of a number of recent research reports. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of NPS Pharmaceuticals in a research note on Friday, August 15th. Separately, analysts at FBR Capital Markets initiated coverage on shares of NPS Pharmaceuticals in a research note on Thursday, August 14th. They set an “outperform” rating and a $34.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of NPS Pharmaceuticals in a research note on Thursday, August 7th. They now have a $26.00 price target on the stock, up previously from $25.00.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.